Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026
Rhea-AI Summary
Phio Pharmaceuticals (NASDAQ: PHIO) will host a live virtual fireside chat with Force Family Office on May 19, 2026 at 4 PM EDT, focused on innovations in skin cancer treatment and prevention.
Recent highlights include Phase 1b data for PH-762 showing no dose-limiting toxicities or serious adverse events among 22 treated patients, a reported ~65% pathological response rate in cSCC (including 6 of 7 responders in the highest-dose cohort), targeted FDA engagement in Q2 2026, and cash projected to fund operations into the first half of 2027.
Positive
- PH-762 Phase 1b: 22 patients treated with no dose-limiting toxicities or serious adverse events
- Approximately 65% pathological response rate in cSCC across all PH-762 dosing cohorts
- Highest-dose PH-762 cohort showed 85% pathological response (6 of 7 cSCC patients)
- FDA engagement for next-stage PH-762 development targeted for Q2 2026
- Cash and cash equivalents projected to fund operations into first half of 2027
Negative
- None.
News Market Reaction – PHIO
In the May 12 session, PHIO gained 1.85%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Earnings and update | Negative | -6.1% | Q1 2026 results with wider net loss and higher R&D plus ATM capacity. |
| Apr 23 | Investor roadshow | Positive | -1.6% | Virtual non-deal roadshow highlighting INTASYL platform and PH-762 data. |
| Apr 13 | Fireside chat | Positive | +2.5% | Force Family Office chat discussing INTASYL and PH-762 Phase 1b results. |
| Apr 09 | Conference presentation | Neutral | -3.9% | Centri Capital Conference talk on PH-762 progress and immuno-oncology strategy. |
| Mar 30 | Manufacturing deal | Positive | -4.8% | U.S. cGMP manufacturing agreement to supply PH-762 for trials and potential launch. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent PHIO news has often centered on PH-762 progress and investor outreach, with mixed price reactions: clinical/manufacturing positives sometimes sold off, while similar fireside chat news drew a modest gain.
Over the last few months, Phio has repeatedly highlighted PH-762’s Phase 1b data—22 patients treated with favorable pathology and no dose-limiting toxicities—alongside plans for an FDA submission in Q2 2026. Events on Mar 30 and Apr 23 stressed manufacturing readiness and virtual roadshows, yet the stock fell 4.76% and 1.6%, respectively. A prior Force Family Office fireside chat on Apr 13 saw a 2.48% gain. The May 10-Q/8-K earnings update, with higher R&D spend and an ATM, coincided with a 6.14% decline.
Key Terms
siRNA medical
gene silencing medical
intratumoral medical
cutaneous squamous cell carcinoma medical
Merkel cell carcinoma medical
pathological response medical
immuno-oncology medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Live virtual fireside chat — investors, advisors, and life sciences analysts invited to attend
Featuring Dermatologist Mary Spellman, M.D., with Phio CEO Robert Bitterman and Force Family Office CEO Steven Saltzstein
King of Prussia, Pennsylvania--(Newsfile Corp. - May 12, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will participate in a fireside chat with Steven Saltzstein, CEO, Force Family Office. Joining them will be Dr. Mary Spellman, Board Certified, licensed dermatologist who will explore both prevention and next-generation treatment strategies for various forms of skin cancer.
"We are excited to take part in this fireside chat with Force Family Office," said Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals. "Dr. Spellman will discuss the future direction of dermatologic oncology and highlight how our INTASYL® siRNA program represents a differentiated and innovative approach to immuno-oncology."
DATE: Tuesday May 19, 2026
TIME: 4 PM EDT
REGISTRATION LINK: PHIO Pharma - Force Family Office
Recent Company Highlights
Phio's lead clinical candidate, PH-762, is being evaluated as an intratumoral therapy in cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma. In its Phase 1b trial, Phio has reported that 22 patients completed treatment across five dose-escalation cohorts, with no dose-limiting toxicities or serious adverse events. The Company has also reported a pathological response rate in cSCC across all dosing cohorts of approximately
Phio has indicated that FDA engagement regarding next-stage clinical development is targeted for the second quarter of 2026 and has reported cash and cash equivalents projected to sustain operations into the first half of 2027.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company advancing its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical development program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.
For additional information, visit the Company's website, www.phiopharma.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements, which include statements, among other things, regarding the anticipated benefits of our INTASYL™ RNAi platform, the results from our ongoing clinical trials, our expectations that our cash runway will extend into the first half of 2027, our expectations regarding timing of FDA submissions intended to propose and seek guidance for next steps in clinical study design for PH-762, our expectations that such FDA submissions and any related FDA meetings will clarify next steps in advancing the PH-762 development program, details regarding our planned non-clinical toxicology study, and our ability to support ongoing clinical development, operational requirements and strategic initiatives with the capital we currently have on hand, are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact of future FDA interactions on the development of our product candidates; the impact to our business and operations by inflationary pressures; recession fears; the development of our product candidates, results from our nonclinical, preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those risks identified in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the U.S. Securities and Exchange Commission. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296886